Abpro Holdings, Inc. is a biotechnology company. The Company is advancing a pipeline of next generation antibody therapies for human epidermal growth factor receptor 2 (HER2)+cancers, non-HER2+ gastric and liver cancer, and wet age-related macular degeneration (AMD) and diabetic macular edema (DME). These antibodies are developed using the Companyâ€™s proprietary DiversImmune platform. Its two lead product candidates, ABP-102 and ABP-201, feature its next generation tetravalent antibody format (TetraBi antibody format), which binds to two different targets with two distinct binding sites per target. ABP-102 is designed to redirect a patientâ€™s immune system to fight cancer by engaging T cells through co-targeting HER2, and CD3, T-cell co-receptor. ABP-201 is designed to block blood vessel formation and normalize damaged vessels through co-targeting VEGF and ANG-2. It plans to develop ABP-201 to treat vascular disease of the eye, focusing on wet age-related macular degeneration (Wet AMD).

Employees

Sector

Biotechnology & Medical Research

More about the company

Market Cap	1.16M 1.01M 936K 874K 1.64M 109M 1.65M 11.12M 4.33M 53.81M 4.35M 4.25M 187M	P/E 2024	-2.41x	P/E 2025	-3.27x
Enterprise Value	1.24M 1.08M 1M 934K 1.75M 117M 1.77M 11.89M 4.63M 57.53M 4.65M 4.55M 200M	EV / Sales 2024	497x	EV / Sales 2025	-
Free-Float	83.91%	Yield 2024 *	-	Yield 2025	-

May. 20	Abpro Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
Apr. 15	Abpro Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
Apr. 14	Abpro Holdings, Inc. Auditor Raises 'Going Concern' Doubt	CI
Feb. 24	Abpro Holdings, Inc.(NasdaqCM:ABP) dropped from S&P TMI Index	CI
Feb. 19	Abpro Holdings, Inc.(OTCPK:ABPO) dropped from NASDAQ Composite Index	CI
Feb. 03	Abpro Holdings, Inc. Announces Board and Committee Resignations	CI
Jan. 23	Abpro Holdings, Inc. Announces Board and Committee Changes	CI
Jan. 16	Abpro Holdings, Inc. announced that it expects to receive $0.147 million in funding	CI
Jan. 06	Abpro, Celltrion Say Solid Cancer Tumor Therapy Investigational New Drug Application Receives US FDA Clearance	MT
Jan. 06	Abpro Holdings, Inc. and Celltrion, Inc. Announce U.S. FDA IND Clearance for Lead Multispecific Antibody Cancer Candidate ABP-102 / CT-P72	CI
Dec. 15	Abpro Holdings announces submission of an IND application to initiate a Phase 1 clinical trial of T cell engager ABP-102/CT-P72 for HER2-positive cancers	RE
Dec. 15	Abpro Holdings, Inc. and Celltrion, Inc. Announces Submission of an IND Application to Initiate a Phase 1 Clinical Trial of T Cell Engager ABP-102/CT-P72 for HER2-Positive Cancers	CI
Nov. 14	Abpro Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI

Jan. 15	Abpro’s Lead Program ABP-102 Featured in Celltrion Presentation at the 44th Annual J.P. Morgan Healthcare Conference	AQ
Jan. 06	Abpro and Celltrion, Inc. Announce U.S. FDA IND Clearance for Lead Multispecific Antibody Cancer Candidate ABP-102 / CT-P72	AQ
Dec. 15	Abpro Holdings Announces Submission of an IND Application to Initiate a Phase 1 Clinical Trial of T cell engager ABP-102/CT-P72 for HER2-positive Cancers	AQ
Dec. 09	Abpro Granted Nasdaq Listing Extension to Pursue Compliance and Strategic Objectives	AQ
Nov. 04	Abpro and Celltrion to Present Preclinical Data for CT-P72/ABP-102 at SITC 2025, Highlighting a Next-Generation HER2×CD3 T-Cell Engager	AQ

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ABPRO CORPORATION	-.--%	-.--%	-	-	1.16M
LONZA GROUP AG	+0.34%	+1.09%	-10.80%	-5.05%	43.13B
REVOLUTION MEDICINES, INC.	+1.08%	+3.00%	+311.74%	+560.23%	34.65B
BEONE MEDICINES AG	+0.13%	+0.80%	+4.98%	+45.41%	30.03B
IQVIA HOLDINGS INC.	-0.67%	-6.49%	+7.51%	-21.91%	28B
CELLTRION, INC.	-1.06%	-2.60%	+9.08%	+21.51%	24.45B
ASCENDIS PHARMA A/S	-0.44%	+2.65%	-	-	14.34B
MEDPACE HOLDINGS, INC.	-2.24%	-3.87%	+45.62%	+100.10%	13.14B
EUROFINS SCIENTIFIC SE	+1.54%	+0.16%	+6.65%	+8.89%	12.53B
IONIS PHARMACEUTICALS, INC.	+2.52%	+2.93%	+102.10%	+84.78%	12.25B
Average	+0.15%	+0.65%	+59.61%	+99.25%	23.61B
Weighted average by Cap.	+0.18%	+1.19%	+64.84%	+115.73%

	2024	2025
Net sales	183K 160K 148K 138K 259K 17.29M 261K 1.76M 684K 8.5M 687K 672K 29.54M	-
Net income	-7.23M -6.32M -5.85M -5.46M -10.24M -683M -10.32M -69.46M -27.03M -336M -27.15M -26.56M -1.17B	-2.89M -2.53M -2.34M -2.18M -4.1M -273M -4.13M -27.78M -10.81M -134M -10.86M -10.62M -467M
Net Debt	478K 418K 386K 361K 677K 45.17M 682K 4.59M 1.79M 22.21M 1.79M 1.76M 77.15M	80K 69.9K 64.66K 60.35K 113K 7.56M 114K 768K 299K 3.72M 300K 294K 12.91M

Abpro Corporation Stock Nasdaq

Stocks

US0008501076

Biotechnology & Medical Research

Valuation: Abpro Corporation

Latest news : Abpro Corporation

Press Releases: Abpro Corporation

Other Biotechnology & Medical Research

Financials

Company Profile